

# **EMMESSAR BIOTECH & NUTRÍTION LIMITED**

29, Kamer Building, 4th floor, 38, Cawasji Patel Street, Fort, Mumbai – 400 001 Tel: 022-49738167/68 Email: <a href="mailto:enquiries@ebnl.org">enquiries@ebnl.org</a> Website: <a href="mailto:www.ebnl.org">www.ebnl.org</a> Investors Grievance Email: <a href="mailto:investors@ebnl.org">investors@ebnl.org</a> CIN No. L24110MH1992PLC065942

## EBN/S-LDF53

February 06, 2021

The Manager
The Department of Corporate Service
BSE Limited
Floor 25, Phiroze Jeejebhoy Towers
Dalal Street, Fort, Mumbai – 400 001

Dear Sir / Madam,

Sub: Outcome of the Board Meeting under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ref: Scrip Code No. 524768

With reference to the captioned subject, please be informed that the Board of Directors of the Company at its meeting held today i.e., 06<sup>th</sup> February, 2021, inter alia, considered and approved

a) the Un-Audited Financial Results along with the Limited Review Report issued by M/s. V. Sankar Aiyar & Co., Chartered Accountants, Statutory Auditors for the quarter and nine months ended 31<sup>st</sup> December, 2020, which has been duly reviewed and recommended by the Audit Committee;

and

b) appointment of Jeyavel Balaiah Nadar (DIN 08163899) as an Executive Director & Chief Financial Officer (CFO) of the Company, on the basis of the recommendation of the Nomination and Remuneration Committee, w.e.f. 06<sup>th</sup> February, 2021.

The Board has also taken on record the existing arrangement of contract manufacturing of Fine Chemicals will lapse on 31.03.2021 and the same is not getting renewed w.e.f. 01.04.2021. Consequently, the entire Turnover / Profit of the Fine Chemical Division will be affected, in the next Financial Year.

The Board Meeting commenced at 02,00 p.m. and concluded at 6.00 p.m.

The Un-Audited Standalone and Consolidated Financial Results will be made available on the Company's website i.e. www.ebnl.org

You are kindly requested to take this on record.

Thanking you,

Yours faithfully,

For Emmessar Biotech & Augition Limited

MSR Ayyangar Managing Director

DIN: 00090266

Regd. Office & Factory: Plot No. T-3/2, MIDC Area, P.O. Box No. 39. Taloja – 410208. Dist. Raigad Maharashtra. Email: <a href="mailto:enquiries@ebnl.org">enquiries@ebnl.org</a> Website: <a href="mailto:www.ebnl.org">www.ebnl.org</a>

#### Regd Office: T-3/2, MIDC, Taloja, Raigad District, Maharashtra State CIN: L24110MH1992PLC06594229 UNAUDITED FINANCIAL RESULTS AS ON 31st DECEMBER 2020 Rs. In Lacs) Unaudited Audited year Nine months Ended Quarter Ended ended 30.09.2020 31.12.2019 31.12.2020 31.12.2020 31.12.2019 31.03.2020 **Particulars** 110.70 107.09 59.28 247.00 253.55 339.59 Revenue from Operations 54.08 36.87 38.06 110.28 109.22 146.51 Ш Other Income 164.78 143.96 97.34 357.28 362.77 486.10 Ш Total Income (I + II) Expenses IV 67.61 58.07 85.10 121.95 209.76 Cost of material consumed 15.34 4.80 13.42 14.22 Purchase of Stock-trade 0.81 (23.75)52.07 (40.84)38.20 (4.52)-69.90 Change in Inventories of Finished goods 46.14 44.68 57.54 **Employee Benefit Expenses** 19.74 14.01 17.61 4.31 4.34 5.78 Depreciation & Amortisation of Assets 1.44 1.44 1.45 Other Expenditure 54.61 15.84 36.39 85.88 101.95 168.55 Total Expenses (IV) 119.65 98.70 73.49 264.43 281.82 385.94 Profit / (loss) from Operations before tax (III - IV) 45.26 23.85 92.85 80.95 100.16 45.13 Exceptional Items 26.40 VI VII Profit / (loss) before Tax 45.13 45.26 23.85 92.85 80.95 73.76 VIII Tax Expense Current Tax (MAT) -16.00 2.05 Deferred Tax 15.66 : MAT Credit 4. Excess / (short) provision of earlier years 0.07 (0.53)-0.10 Net Profit / (loss) after tax (V - W) VII 45.06 45.26 23.85 93.38 80.95 75.37 IX Other Comprehensive Income 0.05 X Total comprehensive income and Other Comprehensive Income 45.06 45.26 23.85 93.38 80.95 75.42 XI 499.61 499.61 499.61 499.61 499.61 499.61 XII Paid-up Equity Share Capital 10.00 10.00 10.00 10.00 10.00 10.00 (Face Value of the share) Earning per Shares 0.90 1.62 1.51 0.91 0.48 1.87 Basic

0.90

**EMMESSAR BIOTECH & NUTRITION LIMITED** 

#### Notes:

Diluted

- The above results were taken on record by the Board of Directors and the Audit Committee at their meeting held on 6th February 2021 and have been subject to Limited Review by the Statutory Auditors. The review report of the Statutory Auditors is being filed with the BSE.
- 2 The Company operates three segments ie. Healthcare, Fine Chemicals and Rent on Leasehold Land.
- 3 Other income includes Rent for the period 01.04.2020 to 17.05.2020 which is now received during the quarter.
- 4 Deferred tax & provision for taxation will be calculated annually.
- The existing arrangement of contract manufacturing of Fine Chemicals will lapse on 31.03.2021 and the same is not getting renewed w.e.f. 01.04.2021. Consequently, the entire turnover / profit of the Fine Chemical Division will be affected in the next Financial Year.
- 6 No Investors Compliant received during the quarter ended 31st December 2020

For Emmessar Biotech & Nutrition Lim

1.87

1.62

1.51

0.48

0.91

MSR Ayyangar Managing Director

DIN: 00090266

Mumbai

6th February 2021

# **EMMESSAR BIOTECH & NUTRITION LIMITED**

Regd Office: T-3/2, MIDC, Taloja, Raigad District, Maharashtra State

CIN: L24110MH1992PLC06594229

Sr. No	Particulars	Unaudited					Audited
		Quarter Ended			Nine Months ended		Year Ended
		31.12.2020	30.09.2020	31.12.2019	31.12.2020	31.12.2019	31.03.2020
1	Segment Revenue						
a	Healthcare	2.80	16.74	5.43	21.13	50.99	53.48
b	Fine Chemicals	107.90	90.35	53.85	225.87	202.56	286.11
С	Rent on leasehold land	51.27	33.78	33.78	101.34	101.35	135.13
d	Others	2.81	3.09	4.28	8.94	7.87	11.38
	Total:	164.78	143.96	97.34	357.28	362.77	486.10
	Less: Inter Segment Revenue				92	125	(*)
	Net Sales / Income from Operations	164.78	143.96	97.34	357.28	362.77	486.10
2	Segment Results (Profit / Loss) before tax						
a	Healthcare	0.74	10.40	3.10	11.82	33.70	34.94
b	Fine Chemicals	19.27	20.81	8.44	43.92	13.97	-11.16
c	Rent on leasehold land	50.85	33.55	33.36	100.08	100.09	135.13
d	Others	2.81	3.09	4.28	8.94	7.87	11.38
	Total:	73.67	67.85	49.18	164.76	155.63	170.29
	Less:			L.			
	Interest			4	i i	o#1	
	Other Unallocable Expenditure (net off)	28.54	22.59	25.33	71.91	74.68	70.13
	Total Profit before Tax	45.13	45.26	23.85	92.85	80.95	100.16
3	Capital Employed					*	
	(Segment Assets - Segment Liabilities)				1 1		
a	Healthcare	8.13	7.20	6.42	8.13	6.42	8.23
b	Fine Chemicals	71.17	74.56	36.88	71.17	36.88	28.9
c	Rent on leasehold land	1.39	1.62	2.59	1.39	2.59	
d	Others	389.23		231.32		231.32	
	Total:	469.92	424.44	277.21	469.92	277,21	326.99

Note: The Fixed Assets are employed for the general enterprise and are not segmental in nature.

The above results were taken on record at a meeting of the Board of Directors held on 6th February, 2021.

Mumbai 6th February 2021 For Emmessar Biotech & Nutrition Limited

MSR Ayyangar Managing Director DIN: 00090266

V. Sankar Aiyar & Co.

CHARTERED ACCOUNTANTS

2-C, Court Chambers

35, New Marine Lines Mumbai – 400 020

Tel : 2200 4465, 2206 7440 Fax : 91-22- 2200 0649 E-mail : mumbai@vsa.co.in

E-mail : mumbai@vsa.co.in
Website : www.vsa.co.in

Independent Auditor's Review Report on Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

# TO THE BOARD OF DIRECTORS OF

### **Emmessar Nutrition & Biotech Limited**

- We have reviewed the accompanying statement of unaudited financial results of Emmessar Biotech & Nutrition Limited ("the Company") for the quarter and nine months ended December 31, 2020.
- 2. This statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For V. Sankar Aiyar & Co., Chartered Accountants (FRN. 109208W)

V Mohan Partner

(Membership No. 017748) UDIN: 21017748AAAAAP9607

Place: Mumbai

Date: February 6, 2021